FOLDCAUTIOUS

FOLD Return on Equity (ROE) Analysis

-11.6%

Higher than 18% of Healthcare sector peers

Updated 1571h ago·SEC filings & market data

Key Takeaway

Amicus Therapeutics’ Return on Equity (ROE) of -11.6% means the company is currently generating a loss relative to the money shareholders have invested—a negative ROE signals unprofitability.

Sector Performance

18th percentile

FOLD

-11.6%

Sector Median

10.1%

Sector Avg

68.8%

Prior Period

-9.9%(May 2026)

↓ Declining

📊

Deep Analysis

Amicus Therapeutics’ Return on Equity (ROE) of -11.6% means the company is currently generating a loss relative to the money shareholders have invested—a negative ROE signals unprofitability.

This performance sits well below its Healthcare sector peers, which have a median ROE of 11.0%, placing FOLD in the 26th percentile among them. The year-over-year change is not available, but the quarter-over-quarter change of -17.2% shows the ROE deepened from -9.9% to -11.6%, a worsening trend. The combination of a deeply negative ROE level and a deteriorating quarter-over-quarter pattern points to elevated investment risk, with no near-term sign of a turnaround in profitability. This negative metric does not support a bullish outlook; however, it aligns with the overall NEUTRAL verdict because it represents a clear weakness that other factors in the analysis may offset, keeping the stock rating balanced.

Frequently Asked Questions

What does the Return on Equity (ROE) tell investors about FOLD?

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.

How is the Return on Equity (ROE) calculated?

Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.

How does FOLD's Return on Equity (ROE) compare to its sector?

FOLD's Return on Equity (ROE) of -11.6% compares to a Healthcare sector median of 10.1%, placing it in the 18th percentile.

Who are FOLD's closest peers by Return on Equity (ROE)?

The closest Healthcare peers by Return on Equity (ROE) include: ALGN (10.1%), TECH (9.0%), BIIB (7.7%), ABT (12.5%), TMO (13.5%).

📚

Learn More About Return on Equity (ROE)

What Is Return on Equity (ROE) and Is Higher Always Better?

Return on equity ROE measures how efficiently a company generates profit from shareholder capital. Learn how to decompose ROE using DuPont analysis and why high leverage can make it dangerous—with Apple and JPMorgan examples.

The Formula

Net Income / Shareholders' Equity

Why It Matters

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.